Evaluating response to biologics in severe asthma: precision or guesstimation? - 05/02/21
Doi : 10.1016/j.resmer.2021.100813
Camille Taillé 1, ⁎ 
: Prof, Philippe Devillier 2, Daniel Dusser 3, Marc Humbert 4, Cyril Maurer 5, Nicolas Roche 3
: Prof, Philippe Devillier 2, Daniel Dusser 3, Marc Humbert 4, Cyril Maurer 5, Nicolas Roche 3 1 Groupe Hospitalier Universitaire AP-HP Nord-Université de Paris, Hôpital Bichat, Service de Pneumologie et Centre de Référence constitutif des Maladies Pulmonaires Rares; Inserm UMR 1152, Paris, France
2 Department of Airway Diseases, Hôpital Foch; Laboratory of Research in Respiratory Pharmacology, VIM-UMR-0092, Université Paris Saclay, Suresnes, France
3 Groupe Hospitalier Universitaire AP-HP Centre – Université de Paris, Hôpital Cochin, Service de Pneumologie, INSERM UMR 1016 (Institut Cochin), Paris, France
4 Université Paris-Saclay, Faculty of Medicine; INSERM UMR_S 999; AP-HP, Service de pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
5 Groupe Hospitalier Intercommunal de Montfermeil, Service de Pneumologie, 10, rue du général Leclerc, Montfermeil, France
⁎Corresponding author: Hôpital Bichat, 46 rue Henri Huchard, 75018, Paris, FranceHôpital Bichat46 rue Henri HuchardParis75018France
In corso di stampa. Manoscritto Accettato.
Disponibile online dal Friday 05 February 2021
This article has been published in an issue click here to access
This article has been published in an issue click here to access
Il testo completo di questo articolo è disponibile in PDF.
© 2021
Pubblicato da Elsevier Masson SAS.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?